Does USP 800 require negative pressure for all sterile hazardous drug compounding?

Not always. USP 800 requires full containment, including a C-PEC inside a negative-pressure, externally vented C-SEC, for any HD API and for Table 1 antineoplastics that need manipulation; USP’s public FAQ describes that C-PEC as externally vented with ISO Class 5 or better air, and your SOP decides the device. USP’s public FAQ says HDs that are not Table 1 antineoplastics or HD APIs may be compounded in a positive-pressure C-SEC if an Assessment of Risk is performed; your Assessment of Risk decides which drugs qualify and what controls you use.

Can one Assessment of Risk cover all our NIOSH Table 2 drugs?

No. USP 800 requires the AoR to document alternatives for specific dosage forms, and USP’s public FAQ says it must list each drug and dosage form individually; your AoR decides the controls for each one.

Can we use a laminar airflow workbench (LAFW) or CAI for sterile HDs?

USP’s public FAQ says an LAFW cannot be used for Table 1 antineoplastics or HD APIs, and that an LAFW or CAI does not protect the worker from HDs. For other sterile-to-sterile HD work, the same FAQ leaves it to a documented Assessment of Risk: your Assessment of Risk decides whether one is acceptable, and USP 800 requires the alternative controls to be documented in it.

Who owns the HD list and the Assessments of Risk?

USP 800 requires a designated person to develop and implement procedures and oversee compliance, and USP’s public FAQ says a facility may assign more than one; your SOP decides who maintains the HD list and signs each AoR.

Do we have to compound every sterile hazardous drug in negative pressure, or can Assessment of Risk cover some HDs?

USP 800 requires full containment for any HD API, and for NIOSH Table 1 antineoplastic drugs that need manipulation. For sterile work, USP 800 requires the C-PEC to sit inside a negative-pressure, externally vented C-SEC. For other HDs (and final dosage forms that need only counting or repackaging, unless the manufacturer says otherwise), USP 800 allows an Assessment of Risk (AoR). The AoR is not a blanket “skip the haz room” card.

Negative pressure is not automatic for every sterile hazardous drug, and an Assessment of Risk is not a free pass. Here is where USP 800 draws the line, what the AoR has to show, and where your SOP takes over.

Start Free Demo

Bench split: mandatory full containment vs AoR-eligible HDs

USP 800 requires full containment for any HD API, and for NIOSH Table 1 antineoplastics that need manipulation; for other NIOSH HDs and eligible final dosage forms, your Assessment of Risk decides whether alternative containment and/or work practices apply.

Reconstitution and dilution of Table 1 antineoplastics: USP 800 requires full containment for Table 1 antineoplastics that need manipulation beyond counting or repackaging; your SOP and Designated Person decide how reconstitution and dilution steps are classified, and the safe default is to keep them in the haz suite until your licensed chapter and Designated Person review say otherwise.

USP 800 requires a negative-pressure C-SEC unless a performed and implemented AoR sets alternative controls; USP’s public FAQ says HDs that are not Table 1 antineoplastics or HD APIs may be compounded in a positive-pressure room under an AoR, and your AoR decides which drugs qualify.

The AoR comes first. USP 800 requires the AoR to be done and implemented before any alternative applies; your AoR and SOPs decide which alternative controls and work practices you actually use.

What an AoR must cover

USP 800 requires the AoR to consider each HD type and dosage form and to document alternatives for specific dosage forms; USP’s public FAQ says a single group-level Table 1 or Table 2 AoR is not enough, so your AoR lists each drug and dosage form and decides its controls.

USP 800 requires the AoR to consider HD type, dosage form, exposure risk, packaging, and manipulation; your AoR decides and documents the specific alternative controls (for example unit-dose packaging, reassigning pregnant staff, or extra PPE; these are examples, not an automatic safe list).

If you use an AoR, USP 800 requires the AoR to be reviewed on a set interval and the review documented; confirm the interval in your licensed chapter. Your SOP sets the review calendar and who signs off.

Sterile HD engineering controls when full containment applies

USP 800 requires sterile HDs to be compounded in a C-PEC inside an externally vented, negative-pressure C-SEC; USP’s public FAQ says that C-PEC must be externally vented with ISO Class 5 or better air, such as a Class II BSC or CACI, so confirm that in your licensed chapter, and your SOP decides the device. That C-SEC must meet USP 800, including negative pressure; take the exact pressure and air-change values from your licensed chapter.

USP 800 requires full containment for HD APIs and Table 1 antineoplastics that need manipulation; USP’s public FAQ says an LAFW cannot be used for those and that an LAFW or CAI gives the worker no HD protection, so confirm that in your licensed chapter, and your AoR decides whether either is ever acceptable for other HDs, with the alternative controls documented in it.

For sterile HD CSPs, the USP 797 overlay for Category, C-SCA, and BUD limits comes from your licensed USP 797; confirm it there.

Room layout is a separate question. For where the C-PEC sits inside the C-SEC, read Where must a C-PEC sit when compounding hazardous drugs under USP 800?. This page covers which HDs need full containment and which can go through an AoR.

What sites often misunderstand

USP 800 lets an AoR cover dosage forms of other HDs, not just counting and storage; USP’s public FAQ gives reconstituting, mixing, and diluting Table 2 HDs as an example, and your AoR decides which steps it covers.

USP 800 sorts containment by HD type, dosage form, and whether the drug needs manipulation beyond counting or repackaging; your SOP decides how reconstitution and dilution steps are classified for each drug. Whether a given step also counts as “compounding” is a USP 797 question for your licensed text and your SOP; confirm it in your licensed USP 797.

Under USP 800, full containment applies unless an AoR is performed and implemented; if you take that route, the chapter requires you to document the alternative containment strategies and work practices for specific dosage forms. Your AoR decides whether a Table 2 drug can move to a positive-pressure room and with which controls. USP’s public FAQ allows that move only under an AoR, so Table 2 status alone is not a free pass.

NIOSH list and “antineoplastic” for USP 800

USP’s public FAQ says that for USP 800, antineoplastic means the antineoplastic drugs in Table 1 of the current NIOSH list, so confirm that in your licensed chapter; your HD list decides how each drug on your formulary is classified.

NIOSH’s 2024 list (not USP) decides what sits in Table 1 vs Table 2. In the 2024 list, not every Table 1 drug is antineoplastic, and some antineoplastics sit in Table 2; confirm the current NIOSH list.

Designated Person, SOP, and state board

USP 800 requires a designated person responsible for developing and implementing procedures, overseeing compliance, ensuring personnel competency, and environmental control of storage and compounding areas (USP’s public FAQ says a facility may assign more than one); your SOP decides who maintains the HD list, who signs each AoR, and the review calendar (the AoR review interval itself comes from your licensed chapter, as covered above).

Your state board (and any accreditor) decides whether and how it adopts and enforces USP 800. Check that locally.

Exact pressure and air-change numbers, C-SCA and BUD limits, and what your board enforces come from your licensed USP 800 and USP 797 text, your SOPs, your HD list, and your state board.

When to stay conservative

USP 800 allows alternatives only when an AoR is performed and implemented; without one, use the chapter’s full containment strategies.

When it is unclear whether a Table 1 antineoplastic step is “manipulation,” your SOP and Designated Person decide; a conservative default is the haz suite until the licensed text, current NIOSH classification, and pharmacist and Designated Person review settle it.

Ask Compounding AI Pro with your HD list and the drug in front of you, and it answers with the USP 800 sections cited. Start Free Demo if you are not in the product yet.

FAQ

Does USP 800 require negative pressure for all sterile hazardous drug compounding?: Not always. USP 800 requires full containment, including a C-PEC inside a negative-pressure, externally vented C-SEC, for any HD API and for Table 1 antineoplastics that need manipulation; USP’s public FAQ describes that C-PEC as externally vented with ISO Class 5 or better air, and your SOP decides the device. USP’s public FAQ says HDs that are not Table 1 antineoplastics or HD APIs may be compounded in a positive-pressure C-SEC if an Assessment of Risk is performed; your Assessment of Risk decides which drugs qualify and what controls you use.
Can one Assessment of Risk cover all our NIOSH Table 2 drugs?: No. USP 800 requires the AoR to document alternatives for specific dosage forms, and USP’s public FAQ says it must list each drug and dosage form individually; your AoR decides the controls for each one.
Can we use a laminar airflow workbench (LAFW) or CAI for sterile HDs?: USP’s public FAQ says an LAFW cannot be used for Table 1 antineoplastics or HD APIs, and that an LAFW or CAI does not protect the worker from HDs. For other sterile-to-sterile HD work, the same FAQ leaves it to a documented Assessment of Risk: your Assessment of Risk decides whether one is acceptable, and USP 800 requires the alternative controls to be documented in it.
How often do we have to review our Assessment of Risk?: USP 800 requires the AoR to be reviewed on a set interval and the review documented; confirm the interval in your licensed chapter. Your SOP sets the review calendar and who signs off.
Who owns the HD list and the Assessments of Risk?: USP 800 requires a designated person to develop and implement procedures and oversee compliance, and USP’s public FAQ says a facility may assign more than one; your SOP decides who maintains the HD list and signs each AoR.
What if we never did an Assessment of Risk?: USP 800 allows alternative controls only when an AoR is performed and implemented. Without one, use the chapter’s full containment strategies until an AoR is completed and implemented.

Educational information only. Not legal advice. Not an inspection-outcome guarantee. Keep a current USP Compendium subscription. PIC judgment and your board still govern.